BTK and B-cell chronic lymphocytic leukemia: Inhibitors of bruton’s tyrosine kinase (BTK) such as ibrutinib or of BCL-2 like venetoclax and chimeric antigen receptor (CAR)-T cells have increased treatment options and improved outcomes for CLL patients (1–3).